Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...